MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study

benzinga.com/general/biotech/25/05/45217506/exclusive-mira-pharmaceuticals-lead-program-ketamir-2-shows-no-brain-toxicity-in-fda-mandated-stu

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) released results from a neurotoxicity study of Ketamir-2, its novel oral NMDA receptor antagonist, on Tuesday.
The U.S. Food and Drug Administration (FDA) required the study before initiating human dosing in the United States.
The preclinical…

This story appeared on benzinga.com, 2025-05-06 11:16:43.
The Entire Business World on a Single Page. Free to Use →